The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial

Tjeerd van der Veer; Johanna Margaretha de Koning Gans; Gerrit J. Braunstahl; Angelina L.P. Pieters; Johanna M.W. van den Berg; Rogier A.S. Hoek; Lieke S.J. Kamphuis; Marleen Bakker; Alain V.F. Dubois; Joachim G.J.V. Aerts; Menno M. van der Eerden

doi:10.1183/13993003.00186-2023

The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial

Tjeerd van der Veer^*, Johanna Margaretha de Koning Gans, Gerrit J. Braunstahl, Angelina L.P. Pieters, Johanna M.W. van den Berg, Rogier A.S. Hoek, Lieke S.J. Kamphuis, Marleen Bakker, Alain V.F. Dubois, Joachim G.J.V. Aerts, Menno M. van der Eerden

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Abstract

Bronchiectasis is a chronic inflammatory condition of the airways with a high symptom burden, which includes chronic cough. The current management strategy includes identifying aetiology, comorbidity and treatable traits. The role of inhaled corticosteroids (ICS) with or without long-acting beta agonists (LABA) in treatment is uncertain. ICS use is only advised for patients with coexisting asthma or COPD. However, up to 53.1% of bronchiectasis patients use ICS or ICS/LABA, with a third having no asthma or COPD diagnosis, according to a recent EMBARC analysis (European Multicentre Bronchiectasis Audit and Research Collaboration).

Original language	English
Article number	2300186
Journal	European Respiratory Journal
Volume	61
Issue number	6
DOIs	https://doi.org/10.1183/13993003.00186-2023
Publication status	Published - Jun 2023

Bibliographical note

Access to Document

10.1183/13993003.00186-2023

Cite this

van der Veer, T., de Koning Gans, J. M., Braunstahl, G. J., Pieters, A. L. P., van den Berg, J. M. W., Hoek, R. A. S., Kamphuis, L. S. J., Bakker, M., Dubois, A. V. F., Aerts, J. G. J. V., & van der Eerden, M. M. (2023). The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial. European Respiratory Journal, 61(6), Article 2300186. https://doi.org/10.1183/13993003.00186-2023

@article{59e27cb2523042548dbda72bc97421cd,

title = "The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial",

abstract = "Bronchiectasis is a chronic inflammatory condition of the airways with a high symptom burden, which includes chronic cough. The current management strategy includes identifying aetiology, comorbidity and treatable traits. The role of inhaled corticosteroids (ICS) with or without long-acting beta agonists (LABA) in treatment is uncertain. ICS use is only advised for patients with coexisting asthma or COPD. However, up to 53.1% of bronchiectasis patients use ICS or ICS/LABA, with a third having no asthma or COPD diagnosis, according to a recent EMBARC analysis (European Multicentre Bronchiectasis Audit and Research Collaboration).",

author = "{van der Veer}, Tjeerd and {de Koning Gans}, {Johanna Margaretha} and Braunstahl, {Gerrit J.} and Pieters, {Angelina L.P.} and {van den Berg}, {Johanna M.W.} and Hoek, {Rogier A.S.} and Kamphuis, {Lieke S.J.} and Marleen Bakker and Dubois, {Alain V.F.} and Aerts, {Joachim G.J.V.} and {van der Eerden}, {Menno M.}",

note = "Copyright {\textcopyright}The authors 2023",

year = "2023",

month = jun,

doi = "10.1183/13993003.00186-2023",

language = "English",

volume = "61",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "6",

}

van der Veer, T, de Koning Gans, JM, Braunstahl, GJ , Pieters, ALP, van den Berg, JMW, Hoek, RAS , Kamphuis, LSJ , Bakker, M, Dubois, AVF, Aerts, JGJV & van der Eerden, MM 2023, 'The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial', European Respiratory Journal, vol. 61, no. 6, 2300186. https://doi.org/10.1183/13993003.00186-2023

The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial. / van der Veer, Tjeerd; de Koning Gans, Johanna Margaretha; Braunstahl, Gerrit J. et al.
In: European Respiratory Journal, Vol. 61, No. 6, 2300186, 06.2023.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis

T2 - the FORZA randomised-controlled trial

AU - van der Veer, Tjeerd

AU - de Koning Gans, Johanna Margaretha

AU - Braunstahl, Gerrit J.

AU - Pieters, Angelina L.P.

AU - van den Berg, Johanna M.W.

AU - Hoek, Rogier A.S.

AU - Kamphuis, Lieke S.J.

AU - Bakker, Marleen

AU - Dubois, Alain V.F.

AU - Aerts, Joachim G.J.V.

AU - van der Eerden, Menno M.

PY - 2023/6

Y1 - 2023/6

N2 - Bronchiectasis is a chronic inflammatory condition of the airways with a high symptom burden, which includes chronic cough. The current management strategy includes identifying aetiology, comorbidity and treatable traits. The role of inhaled corticosteroids (ICS) with or without long-acting beta agonists (LABA) in treatment is uncertain. ICS use is only advised for patients with coexisting asthma or COPD. However, up to 53.1% of bronchiectasis patients use ICS or ICS/LABA, with a third having no asthma or COPD diagnosis, according to a recent EMBARC analysis (European Multicentre Bronchiectasis Audit and Research Collaboration).

AB - Bronchiectasis is a chronic inflammatory condition of the airways with a high symptom burden, which includes chronic cough. The current management strategy includes identifying aetiology, comorbidity and treatable traits. The role of inhaled corticosteroids (ICS) with or without long-acting beta agonists (LABA) in treatment is uncertain. ICS use is only advised for patients with coexisting asthma or COPD. However, up to 53.1% of bronchiectasis patients use ICS or ICS/LABA, with a third having no asthma or COPD diagnosis, according to a recent EMBARC analysis (European Multicentre Bronchiectasis Audit and Research Collaboration).

UR - http://www.scopus.com/inward/record.url?scp=85164233768&partnerID=8YFLogxK

UR - https://www.researchgate.net/publication/371237840_The_effect_of_beclomethasone-formoterol_versus_placebo_on_chronic_cough_in_patients_with_non-CF_bronchiectasis_the_FORZA_randomised-controlled_trial

U2 - 10.1183/13993003.00186-2023

DO - 10.1183/13993003.00186-2023

M3 - Article

C2 - 37263749

SN - 0903-1936

VL - 61

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 6

M1 - 2300186

ER -

The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this